Verona Pharma (VRNA) Achieved Strong Launch for Ensifentrine After FDA Approval
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” first-quarter 2025 investor letter.
Verona Pharma Plc (VRNA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 6,563,340 | $416,706,457 | +3% | 14.68% |
| 2. | Darwin Global Management Abhishek Trehan | 3,923,204 | $245,984,891 | +385% | 16.81% |
| 3. | Maverick Capital Lee Ainslie | 1,783,498 | $113,234,288 | -43% | 2% |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 1,631,000 | $103,552,190 | +382% | 0.19% |
| 5. | Hood River Capital Management David Swank | 1,532,348 | $97,288,775 | +4% | 1.66% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.44 | 20,000 | $88,800.00 | 940,003 | 2024-11-18 | Filing | |
| $4.80 | 39,360 | $188,880.77 | 920,003 | 2024-11-06 | Filing | |
| $4.74 | 41,880 | $198,385.56 | 41,880 | 2024-11-06 | Filing | |
| $2.87 | 36,000 | $103,320.00 | 880,643 | 2024-08-12 | Filing | |
| $1.84 | 33,736 | $61,973.03 | 144,800 | 2023-11-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.53 | 80,000 | $922,000.00 | 359,999 | 2025-06-16 | Filing | |
| $11.40 | 400,000 | $4,560,360.00 | 12,278,992 | 2025-06-11 | Filing | |
| $11.40 | 400,000 | $4,560,520.00 | 13,190,168 | 2025-06-11 | Filing | |
| $9.33 | 204,864 | $1,911,667.93 | 12,678,992 | 2025-05-29 | Filing | |
| $9.30 | 162,704 | $1,513,293.63 | 12,883,856 | 2025-05-28 | Filing |
Institutional Investors' Holdings
News See All
Roth Capital Hikes Verona Pharma's (VRNA) Price Target to $116 On COPD Market Prospects
Verona Pharma plc (NASDAQ:VRNA) is one of the 10 biotech stocks screaming a buy. On June 17, Roth Capital increased its price target to $116 from $92 while reiterating a Buy rating.
10 Biotech Stocks Screaming a Buy
The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF.
Jefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre Launch
Verona Pharma plc (NASDAQ:VRNA) is among the 10 Best Growth Stocks Under $100 to Buy Now.
10 Best Growth Stocks Under $100 to Buy Now
Even if asked by a layman where they would want to invest, the answer would be straight: growth stocks.
Jim Cramer Notes Verona Pharma plc (VRNA) “Loses a Lot of Money”
We recently published a list of Jim Cramer Put These 14 Stocks Under the Microscope.
Jim Cramer Put These 14 Stocks Under the Microscope
On Monday's episode of Mad Money, host Jim Cramer made it clear that he believes artificial intelligence remains a powerful force in the business world, especially among the largest technology companies...
11 Best Performing Healthcare Stocks to Buy Now
On April 15, CNBC reported that President Trump's healthcare-focused executive order brought in a win for the sector.
What Makes Verona Pharma plc (VRNA) a Good Investment?
Buckley Capital Advisors, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Verona Pharma plc (NASDAQ:VRNA) Q1 2025 Earnings Call Transcript
Operator: Welcome to Verona Pharma plc's First Quarter 2025 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a listen-only mode.
Billionaire Hedge Funds
